Status:
COMPLETED
Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Early Stages NSCLC
Lead Sponsor:
Eli Lilly and Company
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Preoperative chemotherapy is considered to play a role in early stage non small cell lung cancer (NSCLC) .The use of preoperative Cisplatin/Gemcitabine chemotherapy has proven feasible and without exc...
Eligibility Criteria
Inclusion
- Main inclusion Criteria:
- Must have pathologic documentation of non-small cell lung cancer, IB, II, IIIA.
- ECOG Performance Status of 0 - 1
- Bidimensionally measurable disease or evaluable disease
- Adequate organ function
- Main exclusion Criteria:
- Have greater than Grade 1 neuropathy - motor/sensory
- Significant history of cardiac disease
- Pleural effusion
Exclusion
Key Trial Info
Start Date :
September 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
263 Patients enrolled
Trial Details
Trial ID
NCT00191126
Start Date
September 1 2000
End Date
September 1 2007
Last Update
September 12 2019
Active Locations (37)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician.
Leuven, Belgium
2
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician.
Liège, Belgium
3
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician.
Sarajevo, Bosnia and Herzegovina
4
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST) or speak with your personal physician.
Sofia, Bulgaria